| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 12.77 | 44.9% | 38.5% |
| Total Income | 12.77 | 44.9% | 38.5% |
| Expenditure | 45.74 | 18.0% | 28.0% |
| PBT | -30.26 | 172.6% | 27.2% |
| Net Profit | -27.08 | 120.2% | 13.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | — |
Monte Rosa Therapeutics Announces Q3 2025 Financial Results
04 May 2026 · 4 May, 7:44 am
Summary
Monte Rosa Therapeutics announced its third quarter 2025 financial results, reporting collaboration revenue of $12.8 million, an increase from $9.2 million in the same quarter of the previous year. Research and development expenses increased to $36.7 million, driven by advancements in clinical programs and the QuEEN™ discovery engine. The company's cash position remains strong at $396.2 million, bolstered by a $120 million upfront payment from Novartis. Monte Rosa anticipates its current cash reserves will fund operations through 2028. The company is advancing multiple clinical programs and collaborations, including a second agreement with Novartis.
Key Highlights
- 1
Monte Rosa Therapeutics reported collaboration revenue of $12.8 million for the third quarter of 2025, compared to $9.2 million for the third quarter of 2024.
- 2
Research and Development expenses for the third quarter of 2025 were $36.7 million, compared to $27.6 million for the third quarter of 2024.
- 3
The company's cash, cash equivalents, restricted cash, and marketable securities totaled $396.2 million as of September 30, 2025.
- 4
Monte Rosa received an upfront payment of $120 million from Novartis in September 2025 as part of a collaboration agreement.
- 5
The company expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures through 2028.
- 6
A second agreement was signed with Novartis to develop novel degraders for immune-mediated diseases, providing an upfront payment of $120 million plus option maintenance payments.
- 7
Phase 1 study of NEK7-directed MGD MRT-8102 is underway, with initial readout including data from high-CVD risk cohort on track for H1 2026.
Management Comments
Markus Warmuth
“With three programs in clinical development and a highly productive drug discovery engine creating additional future opportunities, we are building a leading protein degradation company innovating in the molecular glue degrader space. In that context, our recently announced second collaboration with Novartis marks another major milestone for Monte Rosa, significantly expanding our potential impact on immune-mediated diseases. We believe this partnership further validates the breadth and versatility of our QuEEN™ discovery engine and underscores the growing recognition of MGDs as a distinct and potentially transformative therapeutic modality. Our cash runway extends beyond multiple anticipated Phase 2 readouts for MRT-8102, MRT-6160, and MRT-2359, and positions us to execute on our early-stage portfolio, including multiple undisclosed targets in Th1, Th2, and Th17-driven autoimmune conditions.” “In regard to our clinical programs, we are enrolling our Phase 1 study of MRT-8102, the only clinical-stage degrader targeting NEK7, which we believe offers a highly differentiated approach to potentially address a wide range of inflammatory and cardio-immunology indications driven by the NLRP3 inflammasome, IL-1β and IL-6. We have recently initiated dosing a cohort of subjects with elevated cardiovascular disease (CVD) risk to evaluate changes in well-validated biomarkers such as C-reactive protein. Initial MRT-8102 data from the healthy volunteer and elevated CVD-risk subject cohorts are on track for the first half of 2026. In addition, we continue to work with Novartis to advance MRT-6160, our VAV1-directed MGD, towards Phase 2 studies across multiple indications where alternative treatment options are urgently needed. Our recent preclinical data presentation at ACR Convergence provides further support for exploration of systemic lupus erythematosus, Sjögren's disease, and rheumatoid arthritis, amongst others. In oncology, MRT-2359 continues to progress through expansion in mCRPC, and we plan to share additional data by year-end. We are also making strong progress with our programs targeting cyclin E1 and CDK2, two well-validated tumor drivers poorly addressed by conventional approaches, and we remain on track for an Investigational New Drug (IND) submission next year.”
Informational and educational content only. Not investment advice.